Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Ionis pharmaceuticals, inc. save search
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.94%
H: 1.28%
C: -0.35%
treatment rare disease kidney study phase 3
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Published: 2022-06-21 (Crawled : 07:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 5.44%
H: 0.0%
C: 0.0%
eplontersen phase 3
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Published: 2022-06-03 (Crawled : 11:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.11%
H: 2.24%
C: 1.03%
results phase 3
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Published: 2021-11-18 (Crawled : 20:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 3.11%
H: 0.84%
C: -4.03%
ema phase 3 hereditary angioedema
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Published: 2021-11-02 (Crawled : 12:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 4.68%
H: 0.78%
C: -0.99%
phase 3
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -6.67%
H: 0.7%
C: -8.03%
phase 3 als
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Published: 2021-09-15 (Crawled : 12:15) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.58%
H: 4.44%
C: 2.67%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.03%
H: 1.15%
C: 0.07%
potential phase 3
Non-profit Partnership Spurs Phase 3 Clinical Trial for Patients With Rare Genetic Form Of ALS
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.23%
H: 0.37%
C: -1.97%
partnership genetic phase 3 trial als rare
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Published: 2021-04-05 (Crawled : 12:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.6%
H: 3.61%
C: 3.35%
phase 3 trial als
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.